Eric H. Bjerkholt
2017 - Aimmune Therapeutics
In 2017, Eric H. Bjerkholt earned a total compensation of $3.9M as Chief Financial Officer at Aimmune Therapeutics.
Compensation breakdown
| Bonus | $56,800 |
|---|---|
| Non-Equity Incentive Plan | $116,000 |
| Option Awards | $3,417,012 |
| Salary | $268,333 |
| Total | $3,858,145 |
Bjerkholt received $3.4M in option awards, accounting for 89% of the total pay in 2017.
Bjerkholt also received $56.8K in bonus, $116K in non-equity incentive plan and $268.3K in salary.
Rankings
In 2017, Eric H. Bjerkholt's compensation ranked 2,675th out of 14,666 executives tracked by ExecPay. In other words, Bjerkholt earned more than 81.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,675 out of 14,666 | 82nd |
Division Manufacturing | 927 out of 5,772 | 84th |
Major group Chemicals And Allied Products | 245 out of 2,075 | 88th |
Industry group Drugs | 187 out of 1,731 | 89th |
Industry Pharmaceutical Preparations | 150 out of 1,333 | 89th |
Source: SEC filing on April 11, 2018.
Bjerkholt's colleagues
We found five more compensation records of executives who worked with Eric H. Bjerkholt at Aimmune Therapeutics in 2017.
2017
Stephen Dilly
Aimmune Therapeutics
Chief Executive Officer
2017
Daniel Adelman
Aimmune Therapeutics
Chief Medical Officer
2017
Douglas Sheehy
Aimmune Therapeutics
General Counsel
2017
Jeffrey Knapp
Aimmune Therapeutics
Chief Operating Officer
2017
Warren DeSouza
Aimmune Therapeutics